# Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

> **NCT01435343** · PHASE1,PHASE2 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 55 (actual)

## Conditions studied

- Acute Myeloblastic Leukemia

## Interventions

- **DRUG:** fludarabine
- **DRUG:** Idarubicin
- **DRUG:** cytarabine
- **DRUG:** G-CSF
- **DRUG:** plerixafor

## Key facts

- **NCT ID:** NCT01435343
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-05
- **Final completion:** 2016-12
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435343, "Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01435343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*